certolizumab pegol

Details

Files

Generic Name:

certolizumab pegol

Project Status:

Complete

Therapeutic Area:

Psoriasis, moderate to severe plaque

Manufacturer:

UCB Canada Inc.

Call for patient/clinician input open:

October 15, 2018

Brand Name:

Cimzia

Project Line:

Reimbursement Review

Project Number:

SR0587-000

Call for patient/clinician input closed:

December 3, 2018

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Submission Type:

Initial

Fee Schedule:

Schedule A

Indications:

Psoriasis, moderate to severe plaque

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

November 20, 2019

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones²
Call for patient input posted	October 15, 2018
Patient group input closed	December 03, 2018
Clarification: - Patient input submission received from the Canadian Association of Psoriasis Patients (CAPP), the Canadian Psoriasis Network (CPN), the Canadian Skin Patient Alliance (CSPA), and Psoriasis Society of Canada
Patient input summary sent for review to patient input groups	June 13, 2019
Patient group comments on input summary closed	June 20, 2019
Clarification: - Patient input summary feedback received
Submission received	May 13, 2019
Submission accepted	May 28, 2019
Review initiated	May 29, 2019
Draft CADTH review report(s) sent to sponsor	August 23, 2019
Comments from sponsor on draft CADTH review report(s) received	September 04, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsor	October 03, 2019
Canadian Drug Expert Committee (CDEC) meeting	October 16, 2019
CDEC recommendation sent to sponsor and drug plans	October 30, 2019
Embargo period ended	November 13, 2019
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans	November 20, 2019
CDEC Final Recommendation posted	November 22, 2019
Redaction requests from sponsor on draft CADTH review report(s) received	December 11, 2019
Redacted CADTH review report(s) sent to sponsor and drug plans	December 23, 2019
Validation of redacted CADTH review report(s) received	January 07, 2020
Final CADTH review report(s) posted	January 29, 2020